Back to News
Market Impact: 0.25
Regeneron's Libtayo Wins EMA CHMP Support For Extended Dosing
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Regeneron said the EMA’s CHMP adopted a positive opinion recommending approval of an alternative dosing schedule for Libtayo (cemiplimab). The article excerpt provides no further details on the schedule or the scope of the recommendation.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
REGN0.55
More News
- Stock fixing scandal could see Turkish companies frozen out of global indexes
- MSCI Ignites Indonesia Market Reckoning After Months of Warnings
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated
- Kimberly-Clark is having its best week in four years. Here's what is propelling shares higher
- Trump waives many Russia-related sanctions, tariffs before they were to take effect under new law
- Norway's $2 trillion wealth fund was frozen out of major defense companies. That may be about to change